Jazz Pharmaceuticals heads into late May with shorts in full retreat — a month-long covering wave that has cut short interest nearly in half, even as a fresh wave of analyst upgrades pushes price targets well above the current share price.
The short-covering story is the dominant one. Short interest has fallen from roughly 11.8% of the free float in mid-April to 7.7% now — a drop of more than a third in six weeks, and the steepest sustained decline in the 30-day dataset. The move accelerated after the Q1 earnings print on May 6, when the stock jumped nearly 10% on the day. Shorts who had built positions through April were caught wrong-footed. The pace of covering has slowed this week — SI eased just 2.9% over the past five sessions — suggesting the most urgent exits are largely done. With availability running at a very loose 771%, there is no lending-market tension here: plenty of shares remain available to borrow for anyone who wants to rebuild a short.
Cost to borrow reinforces the same picture. At 0.41% annualised — ticking modestly higher over the past week but still firmly in benchmark territory — there is no premium being demanded to borrow JAZZ shares. The options market adds a degree of caution to what is otherwise a bullish setup. The put/call ratio has climbed to 0.80, running about 1.4 standard deviations above its 20-day average of 0.64. That is a notable shift from April, when the PCR held around 0.49, and reflects more hedging demand in the wake of the rally — but it is far from an extreme reading against the 52-week high of 1.54.
The Street has been emphatically bullish this week. UBS upgraded JAZZ to Buy on May 19, raising its target from $188 to $307. Piper Sandler followed on May 22, lifting its Overweight target from $232 to $301. Barclays, already at Overweight, raised its target again today — this time to $253 from $234. Bernstein initiated coverage at Market Perform with a $229 target, the lone note of restraint in an otherwise one-directional flow of upgrades. The consensus mean target now sits at $253, roughly 7% above the current price of $237.41. Factor scores offer supporting context: the analyst recommendation differential ranks in the 99th percentile of the universe, and 12-month forward EPS estimates also score at the 100th percentile — meaning analysts have not only turned bullish but are raising numbers at a rate that outpaces almost every peer. The PE multiple, at around 9.3x, and EV/EBITDA near 8.3x, look undemanding relative to the pace of estimate revision.
The insider picture is the one signal pointing in the other direction. Founder and Chairman Bruce Cozadd sold shares on May 1 for approximately $1.2 million, following a pattern of regular disposals — he also sold in April and early March. A cluster of C-suite executives (CMO, CCO, Chief Accounting Officer, a senior vice president) also sold on March 5, near the $188-$189 level, which now looks like a poorly timed exit given the stock's 26% gain since. The sells were relatively small as a percentage of company shares and carry low trade-significance scores, so they are consistent with scheduled disposal plans rather than a directional signal. Nonetheless, the absence of any insider buying stands out against the bullish analyst backdrop.
Earnings are next due on August 5. The two most recent prints each produced gains of 7-10% on the day and roughly the same over the five-day window — a consistent pattern of post-earnings strength. The next print will be watched for whether Epidiolex and the neurology franchise can sustain the growth rate that prompted this month's upgrade wave, and whether the sodium oxybate franchise holds firm against competition.
See the live data behind this article on ORTEX.
Open JAZZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
